Breaking News
Gilead Sciences
About Gilead Sciences
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.
Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world.
For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong.
At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?”
Trodelvy Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
February 20 2023
Gilead Sciences has announced new and updated positive results from three cohorts of the Phase 2 […]
Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
January 18 2023
Strata Oncology, a next-generation precision oncology company enabling smarter and earlier cancer treatment, has today […]
Gilead Sciences Completes Acquisition of MiroBio
September 22 2022
GMiroBioilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to […]
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-yearly HIV Treatment Option
August 23 2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted Marketing […]
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
August 16 2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the […]
Gilead Sciences to Acquire MiroBio
August 5 2022
Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring […]
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
June 24 2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 […]
Curebase Secures $40 Million in Series B Funding
May 5 2022
Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in […]
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
May 3 2022
Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance […]
Biktarvy ® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
February 14 2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of cumulative 5-year results from two […]
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
January 24 2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) […]
Trodelvy ® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
November 24 2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing […]
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
November 5 2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that data at […]
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
June 29 2021
Kite, a Gilead Company (Nasdaq: GILD), today announced top-line results from the primary analysis of […]